Anteris Technologies reported 2025 financial results showing net operating cash outflows of $77.8 million, reflecting heightened spending across clinical development and manufacturing operations. The increased cash burn underscores the company's accelerated investment in bringing its innovative transcatheter heart valve technology to market.
The company achieved several significant clinical and regulatory milestones during the period. Anteris initiated the PARADIGM Trial, a global clinical study evaluating its DurAVR® transcatheter heart valve, and secured FDA Investigational Device Exemption (IDE) approval to advance the program. These developments represent critical steps in the regulatory pathway toward potential commercialization of the technology.
To support its expansion efforts, Anteris completed a strategic capital raise of $320 million, which included investment from Medtronic, a major player in cardiovascular medical devices. The funding round positions the company to advance clinical trials, scale manufacturing capabilities, and prepare for potential market entry of the DurAVR® platform.